LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback